Home Biosimilar Antibodies Endocrinology & Hormones ANGPTL Evinacumab(anti-ANGPTL3)
For research use only. Not for use in humans.

Evinacumab(anti-ANGPTL3)

Synonyms: ANG-5， ANGL3

Evinacumab is a monoclonal antibody that targets, binds to, and pharmacologically inhibits ANGPTL3, which can act as a complementary agent to other LDL-C lowering regimens for patients aged 12 or older with HoFH.

Evinacumab(anti-ANGPTL3)

Quality Control

Batch: A204902 Purity: 98% Protein concentration: 6.5mg/ml Endotoxin Level: ＜1EU/mg
98

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Evinacumab is a monoclonal antibody that targets, binds to, and pharmacologically inhibits ANGPTL3, which can act as a complementary agent to other LDL-C lowering regimens for patients aged 12 or older with HoFH.

Product Details

CAS No. 1446419-85-7
Molecular Weight 150 kDa
Isotype human IGg1, λ
Application Evinacumab(anti-ANGPTL3)
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07271186 RECRUITING Drug: ALN-ANG3|Drug: Evinacumab|Drug: ALN-ANG3 placebo|Drug: Diabetic Kidney Disease (DKD) Regeneron Pharmaceuticals 2026-01-09 PHASE2
NCT05611528 COMPLETED Drug: Evinacumab Homozygous Familial Hypercholesterolemia Daniel Gaudet 2023-02-21 PHASE3
NCT03409744 COMPLETED Drug: evinacumab Homozygous Familial Hypercholesterolemia Regeneron Pharmaceuticals 2018-03-13 PHASE3
NCT04863014 TERMINATED Drug: evinacumab Hypertriglyceridemia Regeneron Pharmaceuticals 2021-07-12 PHASE2
NCT04233918 COMPLETED Drug: Evinacumab Homozygous Familial Hypercholesterolemia Regeneron Pharmaceuticals 2020-06-29 PHASE3
NCT03175367 COMPLETED Drug: Evinacumab|Drug: Matching placebo Hypercholesterolemia Regeneron Pharmaceuticals 2017-11-10 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-10)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.